



April 19, 2016
SBI Biotech Co., Ltd.

**SBI Biotech's Licensed product, an Anti-ILT7 antibody, has IND approval to initiate
a Phase I Clinical Trial**

SBI Biotech Co., Ltd. (Head office: Minato-ku, Tokyo; President: Takeshi Irie; "SBI Biotech") hereby announces that MedImmune, the global biologics research and development arm of AstraZeneca and the licensee, will initiate a Phase I Clinical trial of an Anti-ILT7 antibody.

SBI Biotech and MedImmune entered into a licensing and collaboration agreement in September of 2008 to develop an antibody to the ILT7 antigen. Under this agreement, MedImmune has been developing an antibody drug and will initiate a Phase 1 Clinical Trial during the third quarter of 2016.

In this Clinical Trial, MedImmune will evaluate the safety of the antibody in patients who suffer from any one of a selected range of autoimmune diseases. These diseases will be the eventual target indications of the product.

For further information, please contact:

SBI Biotech Co., Ltd.

Business Planning Division

Phone number: +81-3-6229-0787

About the anti-ILT7 antibody

ILT7 is a cell surface protein expressed on plasmacytoid dendritic cells (pDCs). The anti-ILT7 antibody has potential in treating autoimmune diseases because pathogenic roles of pDCs have been implicated in various autoimmune diseases such as systemic lupus erythematosus (SLE).